Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
ALEMBIC PHARMA TEVA PHARMA |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ALEMBIC PHARMA Mar-23 |
TEVA PHARMA Dec-13 |
ALEMBIC PHARMA/ TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 792 | 3,486 | - | |
Low | Rs | 463 | 3,028 | - | |
Sales per share (Unadj.) | Rs | 287.6 | 2,000.5 | - | |
Earnings per share (Unadj.) | Rs | 17.4 | 125.0 | - | |
Cash flow per share (Unadj.) | Rs | 31.4 | 286.7 | - | |
Dividends per share (Unadj.) | Rs | 8.00 | 109.40 | - | |
Avg Dividend yield | % | 1.3 | 3.4 | 37.9% | |
Book value per share (Unadj.) | Rs | 222.3 | 2,222.2 | - | |
Shares outstanding (eoy) | m | 196.56 | 848.00 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 2.2 | 1.6 | 134.1% | |
Avg P/E ratio | x | 36.1 | 26.1 | 138.5% | |
P/CF ratio (eoy) | x | 20.0 | 11.4 | 175.9% | |
Price / Book Value ratio | x | 2.8 | 1.5 | 192.7% | |
Dividend payout | % | 46.0 | 87.5 | 52.5% | |
Avg Mkt Cap | Rs m | 123,402 | 2,761,843 | 4.5% | |
No. of employees | `000 | NA | 44.9 | 0.0% | |
Total wages/salary | Rs m | 11,691 | 0 | - | |
Avg. sales/employee | Rs Th | 0 | 37,744.4 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 2,357.9 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 56,526 | 1,696,422 | 3.3% | |
Other income | Rs m | 30 | 0 | - | |
Total revenues | Rs m | 56,557 | 1,696,422 | 3.3% | |
Gross profit | Rs m | 6,772 | 464,566 | 1.5% | |
Depreciation | Rs m | 2,754 | 137,123 | 2.0% | |
Interest | Rs m | 502 | 33,320 | 1.5% | |
Profit before tax | Rs m | 3,546 | 294,122 | 1.2% | |
Minority Interest | Rs m | 0 | 1,336 | 0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -193,075 | -0.0% | |
Tax | Rs m | 126 | -3,591 | -3.5% | |
Profit after tax | Rs m | 3,420 | 105,974 | 3.2% | |
Gross profit margin | % | 12.0 | 27.4 | 43.7% | |
Effective tax rate | % | 3.6 | -1.2 | -291.3% | |
Net profit margin | % | 6.1 | 6.2 | 96.8% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 29,139 | 1,145,757 | 2.5% | |
Current liabilities | Rs m | 16,408 | 999,197 | 1.6% | |
Net working cap to sales | % | 22.5 | 8.6 | 260.7% | |
Current ratio | x | 1.8 | 1.1 | 154.9% | |
Inventory Days | Days | 10 | 91 | 10.7% | |
Debtors Days | Days | 7 | 96 | 7.0% | |
Net fixed assets | Rs m | 31,498 | 554,089 | 5.7% | |
Share capital | Rs m | 393 | 4,176 | 9.4% | |
Net worth | Rs m | 43,705 | 1,884,403 | 2.3% | |
Long term debt | Rs m | 0 | 867,418 | 0.0% | |
Total assets | Rs m | 60,637 | 3,876,868 | 1.6% | |
Interest coverage | x | 8.1 | 9.8 | 82.1% | |
Debt to equity ratio | x | 0 | 0.5 | 0.0% | |
Sales to assets ratio | x | 0.9 | 0.4 | 213.0% | |
Return on assets | % | 6.5 | 3.6 | 180.0% | |
Return on equity | % | 7.8 | 5.6 | 139.1% | |
Return on capital | % | 9.3 | 4.9 | 187.8% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 7,240 | 270,322 | 2.7% | |
From Investments | Rs m | -4,476 | -95,786 | 4.7% | |
From Financial Activity | Rs m | -2,620 | -324,269 | 0.8% | |
Net Cashflow | Rs m | 144 | -149,733 | -0.1% |
Compare ALEMBIC PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US)
Compare ALEMBIC PHARMA With: ALEMBIC MARKSANS PHARMA. GENNEX LAB. VENUS REMEDIES BIOCON
Asian share markets are mixed today after US shares extended their losing streak to the longest since January 2024.